Amplia Communications is a privately owned company headquartered in Trinidad and Tobago. Founded in 2017, the company employs approximately 130 individuals and reported $24.0M in revenue as of 2023. Functioning as a tier 2 media tech buyer, it specializes in providing telecommunications services across the Caribbean.
On February 17, 2026, Amplia announced the initiation of two US sites for its AMPLICITY trial in advanced pancreatic cancer. The University of California Irvine and The Cleveland Clinic will shortly commence recruitment activities, joining the two existing Australian sites at Epworth Hospital in Melbourne and Genesis Care in Sydney. Previously, on December 28, 2025, Dr. Boreham's annual A-Z review of biotechs highlighted Amplia, specifically noting two 'complete responders' in its pancreatic cancer trial. This followed a December 5, 2025, "Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025" report by DelveInsight, which featured Amplia among companies with products in its comprehensive clinical development scenario and growth prospects analysis.
Similar Companies
Subscribe for full access to Amplia Communications's profile
Amplia Communications offers 4 products in the media and telecoms services industry. Amplia Communications's product portfolio comprises of media and TV services and telecoms.
Subscribe for full access to Amplia Communications's products in full detail
Amplia Communications's revenues were less than $50M in 2023. Caretta Research has split Amplia Communications's revenue into 4 different product categories, the largest of which is enterprise broadband and voice. For full access to Amplia Communications's revenue breakdown subscribe to Caretta Portal.
Subscribe for full access to Amplia Communications's revenue in full detail
Subscribe for full access to Amplia Communications's products in full detail 
